The New Jersey–based drugmaker jumped up 40 places on this year’s list—with 62.6% revenue growth—because of the additional sales that came with its $74 billion acquisition of Celgene in 2019. Sales of BMS’s anticoagulant Eliquis and its immuno-oncology drug Yervoy also showed strong growth in 2020. The company won 13 additional drug or formulation approvals in the U.S., European Union, and Japan last year; it also acquired MyoKardia, a biotech focused on cardiovascular diseases, for $13.1 billion in November 2020.
Lists ranking Bristol-Myers Squibb
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...view in list
Latest news for Bristol-Myers Squibb
- NewslettersWhat a Bristol-Myers project to monitor off-label prescribing says about future uses of A.I.January 25, 2022 4:18 PM UTC
- ConferencesLeaders from Peloton, Chobani, and more on how brands earn their purposeOctober 13, 2021 2:15 PM UTC
- HealthBooster shots and a big jump in market value: 3 takeaways from Moderna’s Q2 earningsAugust 5, 2021 9:32 PM UTC
- TechBritish A.I. drug discovery startup Exscientia buys Austrian cancer cell screening companyJune 15, 2021 8:00 AM UTC
- HealthSeniors face steep drug costs as Congress stalls on capping Medicare out-of-pocketsDecember 28, 2020 10:00 AM UTC